Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Purpose: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) are associated with early relapse and poor survival. Quizartinib potently and selectively inhibits FLT3 kinase activity in preclinical AML models.

Patients And Methods: Quizartinib was administered orally at escalating doses of 12 to 450 mg/day to 76 patients (median age, 60 years; range, 23 to 86 years; with a median of three prior therapies [range, 0 to 12 therapies]), enrolled irrespective of FLT3-ITD mutation status in a phase I, first-in-human study in relapsed or refractory AML.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Background: Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma.

Methods: We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy.

Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.

The aim of the study was to determine the prognostic significance of clinical, laboratory and immunological parameters in indolent and aggressive lymphomas, and to evaluate overall survival in different risk category patients. Based on our investigations patients' age, disease stage, number of extra nodal sites involved, patient performance status 2-4 by ECOG, strongly influenced overall survival in the indolent as well as in the aggressive lymphomas. In indolent lymphomas in case of less than three unfavorable prognostic factors patients overall survival was high (41.

Early cardiotoxicity induced by treatment of hematologic malignancies and the risk-factors of its manifestation.

The aim of the study was to determine the incidence of early cardiotoxicity, induced by the treatment of Hemoblastosis and its dependence on the summary dose of antracyclins and other risk-factors (age, sex, pre-existing cardiac diseases). The study revealed that the summary dose of antracyclins is the important risk-factor of cardiotoxicity development. Cardiotoxicity was evident when applying > or =200 mg/m(2) and < or =200 mg/m(2) doses.

Prognostic significance of apoptosis-related CD95 antigen expression in patients with non-Hodgkin's lymphoma.

Apoptosis-related proteins might play an important role in the pathogenesis and sensibility to the chemotherapeutical drugs in patients with non-Hodgkin's lymphoma (NHL). In our study we tried to find out the relation between the expression of CD95/Fas/Apo-1 antigen and clinical outcome of NHL patients. We have measured 24-hour spontaneous apoptosis of peripheral lymphocytes on flow cytometer using specific monoclonal anti-CD95 mouse antibodies in 54 patients aged 19-76 years.